The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer von Berchuck, J.E., Facchinetti, F., DiToro, D.F., Baiev, I., Majeed, U., Reyes, S., Chen, C., Zhang, K., Sharman, R., Uson Junior, P.L.S., Maurer, J., Shroff, R.T., Pritchard, C.C., Wu, M.-J., Catenacci, D.V.T., Javle, M., Friboulet, L., Hollebecque, A., Bardeesy, N., Zhu, A.X., Lennerz, J.K., Tan, B., Borad, M., Parikh, A.R., Kiedrowski, L.A., Kelley, R.K., Mody, K., Juric, D., Goyal, L.

Volltext

Germline Cancer Testing in Unselected Patients with Gastric and Esophageal Cancers: A Multi-center Prospective Study von Uson, P. L. S., Kunze, K. L., Golafshar, M. A., Botrus, G., Riegert-Johnson, D., Boardman, L., Borad, M. J., Ahn, D., Sonbol, M. B., Kahn, A., Klint, M., Esplin, E. D., Nussbaum, R. L., Stewart, A. K., Bekaii-Saab, T., Samadder, N. J.

Volltext

SARS-CoV-2 and Plasmodium falciparum common immunodominant regions may explain low COVID-19 incidence in the malaria-endemic belt von Iesa, M.A.M., Osman, M.E.M., Hassan, M.A., Dirar, A.I.A., Abuzeid, N., Mancuso, J.J., Pandey, R., Mohammed, A.A., Borad, M.J., Babiker, H.M., Konozy, E.H.E.

Volltext

Surface defects incorporated diamond machining of silicon von Khatri, Neha, Barkachary, Borad M, Muneeswaran, B, Al-Sayegh, Rajab, Luo, Xichun, Goel, Saurav

Volltext

Does neoadjuvant treatment in resectable pancreatic cancer improve overall survival? A systematic review and meta-analysis of randomized controlled trials von Uson Junior, P.L.S., Dias e Silva, D., de Castro, N.M., da Silva Victor, E., Rother, E.T., Araújo, S.E.A., Borad, M.J., Moura, F.

Volltext

Numerical Computation and Analysis of Cutting Forces during Nanometric Scratching of Silicon Carbide von Barkachary, Borad M., Joshi, Shrikrishna N.

Volltext

Interim results of fight-202, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with previously treated advanced/metastatic or surgically unresectable chola... von Hollebecque, A., Borad, M., Sahai, V., Catenacci, D.V.T., Murphy, A., Vaccaro, G., Paulson, A., Oh, D.-Y., Féliz, L., Lihou, C., Zhen, H., Abou-Alfa, G.K.

Volltext

HALO 110-101: Phase Ib study of PEGPH20 in combination with cisplatin + gemcitabine (PEGCISGEM) or atezolizumab (ATEZO) + CIS + GEM (PEGCISGEMATEZO) in patients with locally advanc... von Oh, D.-Y., Park, J.-O., Charoentum, C., Stein, S., Noel, M., Chung, V., Wu, W., Alton, R., Muhsin, M., Javle, M., Abou-Alfa, G.K., Borad, M.J.

Volltext

An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202 von Vogel, A., Sahai, V., Hollebecque, A., Vaccaro, G.M., Melisi, D., Al Rajabi, R.M., Paulson, A.S., Borad, M.J., Gallinson, D., Murphy, A.G., Oh, D.-Y., Dotan, E., Catenacci, D.V., Van Cutsem, E., Lihou, C.F., Zhen, H., Veronese, M.L., Abou-Alfa, G.K.

Volltext

A phase IIa trial to assess the safety and efficacy of BL-8040 and pembrolizumab in patients with metastatic pancreatic adenocarcinoma (PDAC) von Hidalgo, M., Epelbaum, R., Wolpin, B.M., Stemmer, S.M., Geva, R., Golan, T., Borazanci, E., Borad, M., Pedersen, K.S., Park, J.O., Ramirez, R., Peled, A., Lustig, T.M., Bohana Kashtan, O., Rosenfeld, O., Sorani, E., Schlienger, K., Vainstein Haras, A., Von Hoff, D.D.

Volltext

Treating HER2-mutant advanced biliary tract cancer with neratinib: benefits of HER2-directed targeted therapy in the phase 2 SUMMIT ‘basket’ trial von Harding, J., Cleary, J., Shapiro, G., Braña, I., Moreno, V., Quinn, D., Borad, M., Loi, S., Spanggaard, I., Stemmer, S., Dujka, M., Cutler, R., Xu, F., Eli, L., Macia, S., Lalani, A., Bryce, R., Bernstam, F. Meric, Solit, D., Hyman, D., Piha-Paul, S.

Volltext

Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FG... von Javle, M., Kelley, R.K., Roychowdhury, S., Weiss, K.H., Abou-Alfa, G.K., Macarulla, T., Sadeghi, S., Waldschmidt, D., Zhu, A.X., Goyal, L., Borad, M., Yong, W.P., Borbath, I., El-Khoueiry, A., Philip, P., Moran, S., Ye, Y., Ising, M., Lewis, N., Bekaii-Saab, T.

Volltext

[18 F]2-fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) response and survival analysis in a phase 1/2 trial of nab-paclitaxel (nab-P) + gemcitabine (gem) for metasta... von Ramanathan, R, Von Hoff, D, Borad, M, Shiansong Li, J, McGovern, D, Renschler, M, Korn, R

Volltext

RNA sequencing of intrahepatic cholangiocarcinoma reveals two prognostic subclasses von Ahn, K.S, O’Brien, D, Kang, Y.N, Kim, Y.H, Kim, T.S, Borad, M, Roberts, L, Kang, K.J

Volltext

P-100Phase IB study of sorafenib + evofosfamide in patients (pts) with advanced hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC): NCCTG N1153 (Alliance) von Borad, M, Renfro, L, Foster, N, Martin, P, Alberts, S, Hubbard, J, Silva, A, Halfdanarson, T, Byrne, T, Erlichman, C

Volltext

4LBA A phase 1 study of first-in-class microRNA-34 mimic, MRX34, in patients with hepatocellular carcinoma or advanced cancer with liver metastasis von Beg, M, Brenner, A, Sachdev, J, Borad, M, Cortes, J, Tibes, R, Kang, Y, Bader, A, Stoudemire, J, Smith, S, Kim, S, Hong, D

Volltext

Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma [Corrigendum] von Babiker, H.M, Riaz, I.B, Husnain, M, Borad, M.J

Volltext

Efficacy of melphalan, arsenic trioxide, and ascorbic acid combination therapy (MAC) in relapsed and refractory multiple myeloma von Borad, M J, Swift, R, Berenson, J R

Volltext

84MO Tumour-only sequencing led to inflated tumour mutational burden estimation especially in under-represented ethnic groups von Asmann, Y., Parikh, K., Borad, M., Bergsagel, L., Mansfield, A.S.

Volltext

Pancreatic cancer models exhibit interferon-independent resistance mechanisms to a Morreton hybrid oncolytic vesiculovirus von Dumbauld, C., Gabere, M., Barro, O., Nagalo, B.M., Borad, M.

Volltext